XML 44 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Note 2 - Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]
  

December 31,

  

December 31,

 
  

2022

  

2021

 

Cash and cash equivalents

 $5,362  $7,504 

Restricted cash included in other assets

  484   475 

Total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows

 $5,846  $7,979 
Schedules of Concentration of Risk, by Product [Table Text Block]
  

For the Years Ended December 31,

 
  

2022

  

2021

 

Avenova Spray

 $7,651  $8,565 

DERMAdoctor

  4,155   649 

NeutroPhase

  976   368 

Other products

  1,592   598 

Total product revenue, net

  14,374   10,180 

Other revenue, net

  30   24 

Total sales, net

 $14,404  $10,204 
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
  

December 31,

  

December 31,

 

Major distribution partner

 2022  2021 

Avenova Spray Pharmacy Distributor A

  30

%

  11

%

Major U.S. Retailer A

  15

%

  *

%

Avenova Spray Pharmacy Distributor B

  11

%

  *

%

Major U.S. Retailer B

  *

%

  33

%

Avenova Spray Pharmacy Distributor C

  *

%

  13

%

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]
  

For the Year Ended December 31, 2021

 
  

As Previously

Reported

  

Selling

Commissions

  

Fulfillment

Fees

  

As Revised

 

Sales

                

Product revenue, net

 $8,397  $870  $913  $10,180 

Cost of goods sold

                

Cost of goods sold

  2,776   -   913   3,689 

Operating expenses

                

Sales and marketing

  7,223   870   -   8,093 
                 

Net loss

  (5,824

)

  -   -   (5,824

)

                 

Net loss per share attributable to common stockholders (basic and diluted)

  (5.26

)

  -   -   (5.26

)

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

For the Years Ended December 31,

 
  

2022

  

2021

 

Numerator

        

Net loss

 $(10,608

)

 $(5,824

)

Less: Preferred deemed dividend

     735 

Less: Retained earnings reduction related to preferred stock down round feature triggered

  5,657    

Net loss attributable to common stockholders, basic and diluted

 $(16,265

)

 $(6,559

)

         

Denominator

        

Weighted average shares of common stock outstanding, basic and diluted

  1,610   1,247 

Net loss per share attributable to common stockholders, basic and diluted

 $(10.10

)

 $(5.26

)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
  

For the Years Ended December 31,

 
  

2022

  2021  

Stock options

  132   127 

Stock warrants

  2,306   202 
   2,438   329